FINWIRES · TerminalLIVE
FINWIRES

CIBC将Celestica的目标股价从425美元上调至480美元,并重申其“跑赢大盘”评级。

By

-- 在Celestica(CLS.TO,CLS)周一公布第一季度财务业绩后,加拿大帝国商业银行资本市场(CIBC Capital Markets)重申了对该公司股票的“跑赢大盘”评级,并将目标股价从425美元上调至480美元。 CIBC表示,Celestica第一季度业绩符合预期,此前该公司面临供应限制,目前这些限制已基本解除。CIBC还补充道,Celestica重申了其“2026-2027年积极的产能扩张计划”,其中包括与关键的“数字原生”客户OpenAI的合作。CIBC认为OpenAI正是OpenAI。 CIBC指出:“短期内,OpenAI可能出现产能过剩,以及供应链可能出现其他短缺,这些因素可能会对市场情绪构成压力。”尽管如此,随着超大规模数据中心运营商(例如谷歌、META 和亚马逊)的资本支出可见性提高,以及2026年下半年产能提升/扩张计划的推进,我们仍然认为市场预期较为保守,并预计随着第一季度财报公布后资本支出假设风险降低,2026年全年业绩预测将持续上调。 加拿大帝国商业银行 (CIBC) 表示,Celestica 的“可见性提升”反映了其在数据中心网络交换机和不断扩展的企业服务器项目领域的领先地位,并补充道,目前“Celestica 的 1.6T 网络项目将在未来几年内逐步推进,预计从2026年底开始,并在2027年加速发展,这得益于众多客户及其战略合作伙伴(包括 AVGO)的支持。” CIBC 还补充道,Celestica 在本季度赢得的新的超大规模数据中心以太网交换机合同(预计将于2027年下半年加速推进)也印证了这一观点。 加拿大帝国商业银行 (CIBC) 表示,尽管第一季度受到供应限制的影响,但这些限制已经缓解,公司有信心在接下来的几个季度中迎头赶上,并能在 2028 年之前支撑市场需求。 CIBC 表示:“我们重申对 Celestica 的‘跑赢大盘’评级,并将此次抛售视为逢低买入良机。我们更新后的目标价为 480 美元,该目标价基于 2027 年预期每股收益 (EPS) 预测的 32 倍(主要)和 2027 年预期息税折旧摊销前利润 (EBITDA) 预测的 24 倍(次要)的综合估值。” CIBC 补充道,Celestica 的目标市盈率反映了“由于模型性能显著提升,人工智能数据中心资本支出上调的预期更加明朗”。

Price: $500.53, Change: $+7.31, Percent Change: +1.48%

Related Articles

Mining & Metals

Primaris REIT Reports Higher Profit, Total Rental Revenue for First Quarter; Full-year Outlook Maintained

Primaris Real Estate Investment Trust (PMZ-UN.TO) after trade Wednesday reported higher total rental revenue and profit for the first quarter and reaffirmed its 2026 outlook.The REIT earned $41.9 million, or $0.305 per unit, in the period, up from $31.2 million, or $0.257, a year ago. Corresponding FactSet figures were not available.Total rental revenue rose to $177.04 million from $150.2 million a year prior. FactSet expected sales of $180.8 million.Among other highlights, Primaris cited funds from operations per average diluted unit of $0.425 compared with $0.439 a year ago. FactSet projected FFO per share of $0.44."Our low leverage, low payout ratio model is a critical pillar to our strategy. We have significant liquidity with the full availability on our unsecured credit facility with no debt maturing in 2026, Chief Financial Officer Rags Davloor said."With strong liquidity, very low leverage, and a low payout ratio, we are well positioned to fund internal growth, enhance portfolio quality, and create long term value for our unitholders," Chief Executive Alex Avery added.The REIT said it is maintaining its full-year 2026 guidance.The REIT's units closed down $0.05 to $18.98 on the Toronto Stock Exchange.

$PMZ-UN.TO
Insider Trading

Maplight Therapeutics Insider Sold Shares Worth $1,347,066, According to a Recent SEC Filing

Anatol Kreitzer, Chief Discovery Officer, on April 27, 2026, sold 45,422 shares in Maplight Therapeutics (MPLT) for $1,347,066. Following the Form 4 filing with the SEC, Kreitzer has control over a total of 211,190 voting common shares of the company, with 211,190 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000202123826000008/xslF345X05/form4-04292026_040429.xml

$MPLT
Insider Trading

Maplight Therapeutics Insider Sold Shares Worth $2,087,687, According to a Recent SEC Filing

Jonathan Gillis, Chief Administrative and Accounting Officer and Principal Accounting Officer, on April 27, 2026, sold 69,835 shares in Maplight Therapeutics (MPLT) for $2,087,687. Following the Form 4 filing with the SEC, Gillis has control over a total of 181,219 voting common shares of the company, with 181,219 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000170995426000008/xslF345X05/form4-04292026_040431.xml

$MPLT